Residual Risk After Statin Therapy:

Slides:

Advertisements

Similar presentations

Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia N Engl J Med Mar 11;362(10): Paul W. Ladenson, M.D., Jens D.

Advertisements

ATP III Guidelines Specific Dyslipidemias. 2 Specific Dyslipidemias: Very High LDL Cholesterol (  190 mg/dL) Causes and Diagnosis Genetic disorders –Monogenic.

Lipid Disorders and Management in Diabetes

Dyslipidemia/Lipid management in Diabetes. M ECHANISMS R ELATING I NSULIN R ESISTANCE AND D YSLIPIDEMIA  TG  Apo B  VLDL (hepatic lipase) Kidney (CETP)CEHDL.

Epanova ® - Omega-3- carboxylic acids Manufacturer: AstraZeneca FDA Approval Date: 05/2014.

THE LIPID PANEL What are we missing? Robert St. Amant, MD, FAAFP Diplomate, American Board of Clinical Lipidology Baton Rouge General Medical Director,

Global impact of ischemic heart disease World Heart Federation, 2011.

Lipid Lowering Substudy Trial of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288: ALLHAT- LLT.

Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.

HCS Objective To determine if measurement of postprandial TG level improves risk prediction of CV events over traditional risk markers in stable patients.

ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.

VBWG HOPE-TOO: Results of the HOPE Study Extension.

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.

DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:

The presence of cardiovascular disease is an important predictor of mortality in patients with end-stage renal disease, as it accounts for almost 50 percent.

Circulation. 2013;128: R4 이태인 / Prof. 우종신.

FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Supplemental Figure S1 (A) (B) Any Statin ↓Randomisation

Triglycerides Cholesterol HDL-C or N NIDDM N or or N IDDM.

The Anglo Scandinavian Cardiac Outcomes Trial

AIM HIGH Niacin plus Statin to prevent vascular events

First time a CETP inhibitor shows reduction of serious CV events

AIM-HIGH Niacin Plus Statin to Prevent Vascular Events

Updates and Perspectives in Diabetic Dyslipidemia

Oxford Niacin Trial.

PCSK9 Inhibitors Post-CVOTs

ACC 2018 Orlando, Florida Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes A Pre-Specified Secondary Endpoint from.

Omega-3 Prescriptions vs Supplements in Practice

Back to the Basics of Dyslipidemia

Clinical Trials in Residual Cardiovascular Risk: A Fresh Perspective

The Chemical Differences Between EPA and DHA.

Select Topics in Cardiovascular Medicine

Managing Complex Hypertension: What Every Physician Should Know

Case Study: 45-year-old Man

What Do We Know About LDL-C?

Managing Hard-To-Treat Hypertension: What Every Physician Should Know

The Chemical Differences Between EPA and DHA.

Diabetes Increases Risk of CVD

An Update on PCSK9 Inhibitors

Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial Erik S.G. Stroes, MD, PhD, Andrey.

A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.

What's New in Dyslipidemia?

CV Risk Doesn't End in the Cath Lab

Personalizing Statin Therapy in Patients With HIV

PCSK9 Inhibitors and Cardiovascular Outcomes

CV Risk Management in T2DM: What Did We Learn from ADA 2016?

CV Risk Doesn't End in the Cath Lab

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Residual CV Risk in Patients With Dyslipidemia and Stable CAD

Advances in Hypertriglyceridemia Treatment

Screening, Lipid Stabilization, and Placebo Run-in

Lipid-Lowering Arm (ASCOT-LLA): Results in the Subgroup of Patients with Diabetes Peter S. Sever, Bjorn Dahlöf, Neil Poulter, Hans Wedel, for the.

Ezetimibe/simvastatin

LRC-CPPT and MRFIT Content Points:

Elevated Admission Plasma Glucose Following ACS

Reducing Risk for CV Outcomes

ACCELERATE Trial design: Patients at high vascular risk were randomized to either evacetrapib 130 mg daily or placebo. They were followed for 30 months.

New Lipid-Lowering Guidelines

HOPE-3 Trial design: Patients without known cardiovascular disease, and with an intermediate risk of cardiovascular events, were randomized in a 2 x 2.

An Update on PCSK9 Inhibitors

2015 EASD In Review: CV Risk management in t2dm

Omega-3s vs Pure EPA in Clinical Practice

Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease Dean G. Karalis, MD Mayo Clinic Proceedings

in diabetic patients with mixed dyslipidemia

BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS

The Elevated Role of GLP-1 RAs in Diabetes Management: Which Patients Should We Aim For?

Specific Dyslipidemias: Very High LDL Cholesterol (>190 mg/dL)

Translating Data From Trial to Practice

Presentation transcript:

Residual Risk After Statin Therapy:

Residual CVD Risk Despite OMT

TG Independently Predicts CVD: Confusion About Adjusting for Non-HDL-C

Lipoprotein Lipase Clears Triglycerides From the Circulation

Recent Genetic Studies Do Support Causality of TGRLP in CV risk

Lipoprotein Lipase: A Central Hub in Metabolism of TGRLP

Overview of TG Metabolism

Elevated TG Concentrations in Non-Statin-Treated Patients Associated With MACE and MI

Increasing TG Levels Increase Risk of Pancreatitis

Assessing TGRLP Levels: Which Method Is Best?

No Fasting Required: Practical Algorithm for Screening and Managing Elevated TG

Treatment Approach for TG ≥ 500 mg/dL to Reduce Risk of Pancreatitis

Treatment Approach for TG 200 to 500 mg/dL

CV Outcomes Trials in Patients With Hypertriglyceridemia

Risk Difference vs Placebo of HTG Subgroups Primary and Secondary CVD Prevention Trials

Why Have CVOTs of TG-Lowering Drugs Failed to Reach Primary Endpoints?

Fish Oil Supplements vs Prescription Omega-3 FAs

What Is on the Horizon?

Conclusion